Iomeprol

Iomeprol
Clinical data
Trade names	Iomervu, others
License data	US DailyMed: Iomeprol;
Routes of; administration	Intravenous, intra-arterial
ATC code	V08AB10 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	none
Elimination half-life	109±20 min
Excretion	Kidney
Identifiers
	IUPAC name 1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	78649-41-9;
PubChem CID	3731;
DrugBank	DB11705;
ChemSpider	3600;
UNII	17E17JBP8L;
KEGG	D01719;
ChEBI	CHEBI:31710;
CompTox Dashboard (EPA)	DTXSID1049061 ;
Chemical and physical data
Formula	C17H22I3N3O8
Molar mass	777.089 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Ic1c(c(I)c(c(I)c1N(C(=O)CO)C)C(=O)NCC(O)CO)C(=O)NCC(O)CO;
	InChI InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31); Key:NJKDOADNQSYQEV-UHFFFAOYSA-N;

Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.^[1]^[2]^[3]

Iomeprol was approved for medical use in the United States in November 2024.^[1]^[4]^[5]

Side effects

It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.^[2] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.^[2]

Society and culture

Iomeprol is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.^[6]

Legal status

Iomeprol was approved for medical use in the United States in November 2024.^[1]^[4]

Brand names

Iomeprol is sold under the brand name Iomervu.^[1]

References

^ ^a ^b ^c ^d ^e fda.gov
^ ^a ^b ^c Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.
^ Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.
^ ^a ^b "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
^ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
^ Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.

[Iomervu_FDA_label-1] ^ ^a ^b ^c ^d ^e fda.gov

[Rossiter_2014-2] Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.

[AC-3] Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.

[Novel_Drug_Approvals_for_2024-4] "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.

[5] New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.

[6] Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.

[1]

[2]

[3]

[4]

[5]

[6]